Karger - Fast Facts Oncology

This is the third episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. DiNardo discusses the missing pieces of MDS management, starting with the latest approvals in MDS treatment and how eligibility for clinical trials is assessed. She also touches on which impacts of transplantation or transformation to acute myeloid leukemia (AML) can be managed. She also touches on the cutting-edge genetic insights that might deliver on the promise of personalized medicine to MDS patients with the most challenging diagnoses. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the second episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. Griffiths discusses what makes Real World Evidence and how it is obtained or archived, the risk stratification of MDS and what that means for gathering evidence, and bridging the gap between the best outcomes of clinical trials and the down-to-Earth results seen in daily clinical practice. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the first episode in our series on myelodysplastic syndromes which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. DeFilipp outlines the current and upcoming treatments for myelodysplastic syndromes. He discusses doublet and triplet combinations that are moving the needle on disease management, including emerging therapies and combinations of hypomethylating agents. He also considers which underlying mutations pose the greatest challenges and/or provide the greatest opportunities for future research in the field. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the third episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Melinda Bachini discusses the use of biomarker testing in cholangiocarcinoma. From the perspective of a patient advocate, she explains how to relay complex information about biomarker testing to patients, and outlines what patients really want to know. She provides advice on how to empower patients to navigate their diagnosis and be the best patient advocates they can possibly be. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the second episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Dr. Marina Baretti discusses the safety of fibroblast growth factor receptor (FGFR) inhibitors, drawing from her clinical experience. She details current safety data, and explains what you need to know about the management of their side effects and adverse events. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the first episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Dr. Sameek Roychowdhury discusses fibroblast growth factor receptor (FGFR) inhibitors in the management of cholangiocarcinoma—how long they’ve been in use, and what we know about their efficacy and toxicity. He uses his clinical experience to share what clinicians really need to know about this treatment, and what to do when disease progresses while on this treatment. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the third episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer. In this episode, Dr. Ben George discusses the importance of real-world data in managing metastatic colorectal cancer care outcomes, and the inescapable truths of daily life that impact patient adherence and resilience. He explains how real-world data can be categorised as providing information on either the efficacy or toxicity of treatment, and how clinicians can use this data to guide management. For more podcast episodes from Karger please visit karger.com/pages/podcasts. This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the second episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer. In this episode, Dr. Reetu Mukherji discusses unmet needs in the treatment landscape of colorectal cancer. She explains where the greatest needs are in current management, and what research is being done to fill those gaps. Topics discussed include: adding checkpoint inhibitors to combinations and the use of novel molecules. Studies discussed include SEAMARK, TRIDENTE, BAYONET, MOUNTAINEER-03, STELLAR-303 among others. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the first episode in our series on colorectal cancer which aims to update clinicians on the latest developments in treatment. In this episode, Dr. Arvind Dasari starts by explaining the current management of colorectal cancer, and then outlines the latest developments in immunotherapy and targeted therapies, touching on specific trials presented at ASCO GI 2023. Trials discussed include Phase III SUNLIGHT, Phase III Fresco-2 and PARADIGM. For more podcast episodes from Karger please visit karger.com/pages/podcasts. This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

Welcome to the third episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer we speak with Dr Hope Rugo, Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr Rugo summarizes the TROPICS02 trial that she presented at this year's conference. We also discuss how data presented from the METEORA and ICON trials add to clinical understandings of immunotherapy response. Coverage is also provided to the ADAPT trial. Finally, we discuss how these clinical improvements in response and progression free survival (PFS) translate to the patient experience.  For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights   For more podcast episodes from Karger please visit https://www.karger.com/podcasts    This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

Welcome to the second episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer, we speak with Dr Shaheenah Dawood, a practicing medical oncologist from Dubai, United Arab Emirates. Dr Dawood discusses the MONARCH3 trial – its background, recent findings and how it differs from the MONARCHER trial. Coverage is also given to the presentations on oral selective estrogen receptor downregulators (SERDs) as a treatment option for breast cancer patients.  For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights   For more podcast episodes from Karger please visit https://www.karger.com/podcasts    This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

Welcome to the first episode in a three-part special live from ESMO 2022. In this episode focused on colorectal cancer, we speak with Dr Chetan Deshmukh, a practicing medical oncologist from Pune, India. Dr Deshmukh discusses the results from the CARIO5 study, which have been presented at the congress. He also shares with us his thoughts on the promise of novel immunotherapeutics and targeted therapies in CRC management and provides his perspective on disparities in drug access in low-middle income countries.  For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights   For more podcast episodes from Karger please visit https://www.karger.com/podcasts   This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

The fifth and final episode of our special series on breast cancer for Karger’s Fast Facts Oncology Podcast. In episode we are joined by Abeda Steenkamp, breast cancer survivor and Service Coordinator for the Cancer Association of South Africa. Join us as we talk about stigma and taboos surrounding breast cancer in South Africa (CANSA). Furthermore, Abeda Kindly shares her own experiences as a breast cancer patient, discusses the important role of education and support, and gives an insight into her work and tasks as a Service Coordinator for CANSA. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting. The sheet is available to download for free from Karger’s platform - https://www.karger.com/WebMaterial/ShowFile/1449609 For more podcast episodes from Karger please visit karger.com/podcasts. Fore more information about the work CANSA and the support that they provide please visit https://cansa.org.za/ This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, A Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

The fourth episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Omar Hamid from Nairobi Kenya. Dr Omar is a clinical oncologist and passionate advocate for affordable cancer care. Listen in as we discuss whether advances in breast cancer treatment are really a boon for patients. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting. The sheet is available to download for free from Karger’s platform - https://www.karger.com/WebMaterial/ShowFile/1449609 For more podcast episodes from Karger please visit karger.com/podcasts. This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, A Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

The third episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are again joined by Dr Shaheenah Dawood, a consultant medical oncologist and professor in clinical oncology from the United Arab Emirates, for the second part of our discussion on the ‘changing landscape in managing breast cancer patients’. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting. The sheet is available to download for free from Karger’s platform - https://www.karger.com/WebMaterial/ShowFile/1449609 For more podcast episodes from Karger please visit karger.com/podcasts. This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, A Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

The second episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Shaheenah Dawood, a consultant medical oncologist and professor in clinical oncology from the United Arab Emirates, to discuss the changing landscape in managing breast cancer patients. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting. The sheet is available to download for free from Karger’s platform - https://www.karger.com/WebMaterial/ShowFile/1449609 For more podcast episodes from Karger please visit karger.com/podcasts. This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, A Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

The first episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Vinicius Knackfuss Gonçalves from the Hospital São Lucas da PUCRS, in Porto Alegre Brazil to discuss the topic of penetration of breast cancer screening in low middle income countries. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting. The sheet is available to download for free from Karger’s platform - https://www.karger.com/WebMaterial/ShowFile/1449609 For more podcast episodes from Karger please visit karger.com/podcasts. This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, A Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.